- Q1 2024 AIM ImmunoTech Inc Earnings Call TranscriptMay 16, 2024$0.39 (-2.40%)Earnings
- Q4 2023 AIM ImmunoTech Inc Earnings Call TranscriptApr 02, 2024$0.45 (-8.18%)Earnings
- AIM ImmunoTech Inc at HC Wainwright Investment Conference - New York TranscriptSep 11, 2023
- Q2 2023 AIM ImmunoTech Inc Earnings Call TranscriptAug 15, 2023$0.6425 (-6.34%)Earnings
- AIM ImmunoTech Inc Investor Summer Spotlight Series TranscriptJul 12, 2023
- Q1 2023 AIM ImmunoTech Inc Earnings Call TranscriptMay 16, 2023$0.42495 (-0.01%)Earnings
- Q4 2022 AIM ImmunoTech Inc Earnings Call TranscriptApr 03, 2023$0.42 (-2.33%)Earnings
- AIM ImmunoTech Inc at H C Wainwright Global Investment Conference (Virtual) TranscriptSep 12, 2022
- AIM ImmunoTech Inc at JTC Team Top Picks Virtual Investor Conference TranscriptJan 26, 2022
- AIM ImmunoTech Inc at SNN Network Virtual Conference TranscriptAug 03, 2020
- AIM ImmunoTech on Commercial Launch in Argentina for Chronic Fatigue and COVID-19 Clinical Trials- Corporate Analyst Meeting TranscriptJul 31, 2020
- CEO Roadshow Interview: Thomas Equels, CEO of AIM Immunotech Corporate Analyst Meeting TranscriptJun 24, 2020
- AIM ImmunoTech greenlit to import chronic fatigue syndrome drug into Argentina Corporate Analyst Meeting TranscriptJun 22, 2020
- AIM ImmunoTech Inc To Describe Their Approach and Progress with Ampligen to Combat COVID-19 TranscriptMay 28, 2020
- AIM ImmunoTech Inc at SNN Planet MicroCap Showcase TranscriptApr 22, 2020
AIM ImmunoTech Inc at SNN Network Virtual Conference Transcript
Greetings, and welcome to the AIM ImmunoTech conference. It is now my pleasure to introduce your host, CEO, Tom Equels. Thank you, Mr. Equels, you may begin.
Hello, everyone. I'm Tom Equels, the CEO of AIM ImmunoTech. First of all, I want to thank you for your interest in our company and our products and the work we're doing. And it's especially important in these troubled times that we're in to have support and understanding the advances that we're trying to make, not just in immunology generally, but also in COVID-19.
We're going to address today an update of our COVID-19 work, our ME/CFS chronic fatigue syndrome work, and our work with COVID-19-induced chronic fatigue and especially our core work that we've done over the past two years in establishing numerous Phase 2 and Phase 1/2 clinical trials in immuno-oncology.
I'm also going to go into an update on our Alferon manufacturing. Alferon is our product, which is a natural alpha interferon. And
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)